Nikolaos A Diakos1, Craig H Selzman1, Frank B Sachse2, Josef Stehlik3, Abdallah G Kfoury3, Omar Wever-Pinzon3, Anna Catino3, Rami Alharethi3, Bruce B Reid3, Dylan V Miller4, Mohamed Salama5, Alexey V Zaitsev2, Junko Shibayama2, Hui Li2, James C Fang3, Dean Y Li6, Stavros G Drakos7. 1. Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program: Divisions of Cardiovascular Medicine and Cardiothoracic Surgery, University of Utah Health Sciences Center, Intermountain Medical Center, Veterans Administration Salt Lake City Health Care System, Salt Lake City, Utah; University of Utah Molecular Medicine Program, Salt Lake City, Utah. 2. Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, Utah. 3. Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program: Divisions of Cardiovascular Medicine and Cardiothoracic Surgery, University of Utah Health Sciences Center, Intermountain Medical Center, Veterans Administration Salt Lake City Health Care System, Salt Lake City, Utah. 4. Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program: Divisions of Cardiovascular Medicine and Cardiothoracic Surgery, University of Utah Health Sciences Center, Intermountain Medical Center, Veterans Administration Salt Lake City Health Care System, Salt Lake City, Utah; Department of Pathology, University of Utah School of Medicine/ARUP Reference Laboratory, Salt Lake City, Utah. 5. Department of Pathology, University of Utah School of Medicine/ARUP Reference Laboratory, Salt Lake City, Utah. 6. University of Utah Molecular Medicine Program, Salt Lake City, Utah. 7. Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program: Divisions of Cardiovascular Medicine and Cardiothoracic Surgery, University of Utah Health Sciences Center, Intermountain Medical Center, Veterans Administration Salt Lake City Health Care System, Salt Lake City, Utah; University of Utah Molecular Medicine Program, Salt Lake City, Utah. Electronic address: stavros.drakos@hsc.utah.edu.
Abstract
BACKGROUND: In animal models of heterotopic transplantation, mechanical unloading of the normal, nonhypertrophic heart results in atrophy. Primarily on the basis of these animal data, the notion that chronic left ventricular assist device (LVAD)-induced unloading will result in atrophy has dominated the clinical heart failure field, and anti-atrophic drugs have been used to enhance the cardiac recovery potential observed in some LVAD patients. However, whether unloading-induced atrophy in experimental normal heart models applies to failing and hypertrophic myocardium in heart failure patients unloaded by continuous-flow LVADs has not been studied. OBJECTIVES: The study examined whether mechanical unloading by continuous-flow LVAD leads to myocardial atrophy. METHODS: We prospectively examined myocardial tissue and hemodynamic and echocardiographic data from 44 LVAD patients and 18 untransplanted normal donors. RESULTS: Cardiomyocyte size (cross-sectional area) decreased after LVAD unloading from 1,238 ± 81 μm(2) to 1,011 ± 68 μm(2) (p = 0.001), but not beyond that of normal donor hearts (682 ± 56 μm(2)). Electron microscopy ultrastructural evaluation, cardiomyocyte glycogen content, and echocardiographic assessment of myocardial mass and left ventricular function also did not suggest myocardial atrophy. Consistent with these findings, t-tubule morphology, cytoplasmic penetration, and distance from the ryanodine receptor were not indicative of ongoing atrophic remodeling during LVAD unloading. Molecular analysis revealed no up-regulation of proatrophic genes and proteins of the ubiquitin proteasome system. CONCLUSIONS: Structural, ultrastructural, microstructural, metabolic, molecular, and clinical functional data indicated that prolonged continuous-flow LVAD unloading does not induce hypertrophy regression to the point of atrophy and degeneration. These findings may be useful in designing future investigations that combine LVAD unloading and pharmaceutical therapies as a bridge to recovery of the failing heart.
BACKGROUND: In animal models of heterotopic transplantation, mechanical unloading of the normal, nonhypertrophic heart results in atrophy. Primarily on the basis of these animal data, the notion that chronic left ventricular assist device (LVAD)-induced unloading will result in atrophy has dominated the clinical heart failure field, and anti-atrophic drugs have been used to enhance the cardiac recovery potential observed in some LVADpatients. However, whether unloading-induced atrophy in experimental normal heart models applies to failing and hypertrophic myocardium in heart failurepatients unloaded by continuous-flow LVADs has not been studied. OBJECTIVES: The study examined whether mechanical unloading by continuous-flow LVAD leads to myocardial atrophy. METHODS: We prospectively examined myocardial tissue and hemodynamic and echocardiographic data from 44 LVADpatients and 18 untransplanted normal donors. RESULTS: Cardiomyocyte size (cross-sectional area) decreased after LVAD unloading from 1,238 ± 81 μm(2) to 1,011 ± 68 μm(2) (p = 0.001), but not beyond that of normal donor hearts (682 ± 56 μm(2)). Electron microscopy ultrastructural evaluation, cardiomyocyte glycogen content, and echocardiographic assessment of myocardial mass and left ventricular function also did not suggest myocardial atrophy. Consistent with these findings, t-tubule morphology, cytoplasmic penetration, and distance from the ryanodine receptor were not indicative of ongoing atrophic remodeling during LVAD unloading. Molecular analysis revealed no up-regulation of proatrophic genes and proteins of the ubiquitin proteasome system. CONCLUSIONS: Structural, ultrastructural, microstructural, metabolic, molecular, and clinical functional data indicated that prolonged continuous-flow LVAD unloading does not induce hypertrophy regression to the point of atrophy and degeneration. These findings may be useful in designing future investigations that combine LVAD unloading and pharmaceutical therapies as a bridge to recovery of the failing heart.
Authors: Michael J Bonios; Antigone Koliopoulou; Omar Wever-Pinzon; Iosif Taleb; Josef Stehlik; Weining Xu; James Wever-Pinzon; Anna Catino; Abdallah G Kfoury; Benjamin D Horne; Jose Nativi-Nicolau; Stamatis N Adamopoulos; James C Fang; Craig H Selzman; Jeroen J Bax; Stavros G Drakos Journal: Circ Cardiovasc Imaging Date: 2018-04 Impact factor: 7.792
Authors: Thomas Seidel; Sutip Navankasattusas; Azmi Ahmad; Nikolaos A Diakos; Weining David Xu; Martin Tristani-Firouzi; Michael J Bonios; Iosif Taleb; Dean Y Li; Craig H Selzman; Stavros G Drakos; Frank B Sachse Journal: Circulation Date: 2017-01-10 Impact factor: 29.690
Authors: Megan E Bowen; Xiaoqing Liu; Peter M Sundwall; Stavros G Drakos; Dean Y Li; Craig H Selzman; Stephen H McKellar Journal: J Thorac Cardiovasc Surg Date: 2017-12-19 Impact factor: 5.209
Authors: Aaron H Healy; Stephen H McKellar; Stavros G Drakos; Antigoni Koliopoulou; Josef Stehlik; Craig H Selzman Journal: J Surg Res Date: 2016-01-20 Impact factor: 2.192
Authors: Palak Shah; Mitchell Psotka; Iosif Taleb; Rami Alharethi; Mortada A Shams; Omar Wever-Pinzon; Michael Yin; Federica Latta; Josef Stehlik; James C Fang; Guoqing Diao; Ramesh Singh; Naila Ijaz; Christos P Kyriakopoulos; Wei Zhu; Christopher W May; Lauren B Cooper; Shashank S Desai; Craig H Selzman; Abdallah G Kfoury; Stavros G Drakos Journal: Circ Heart Fail Date: 2021-05-05 Impact factor: 8.790
Authors: Yankun Lyu; Vipin K Verma; Stavros G Drakos; Frank B Sachse; Younjee Lee; Iosif Taleb; Rachit Badolia; Thirupura S Shankar; Christos P Kyriakopoulos; Craig H Selzman; William Caine; Rami Alharethi; Sutip Navankasattusas; Thomas Seidel Journal: NPJ Aging Mech Dis Date: 2021-05-28